Schizophrenia studies

Investigation of cellbiological effects of cariprazine in patients with mitochondrial schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Hungary

Sponsor

Semmelweis University, STIA-POC-2020

Long-Term Safety and Efficacy of ABT-126 in Subjects with Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom

Sponsor

AbbVie Deutschland GmbH & Co. KG

Metabolic Dysfunctions Associated with Pharmacological Treatment of Schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Spain

Sponsor

Fundación para la Investigación e Innovación Biosanitaria de Asturias (FINBA)

Pregabalin for anxiety comorbidity in patients with schizophrenia (PACS) - A Double-blinded Randomized Placebo Controlled Trial

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Denmark

Sponsor

Aalborg University Hospital, Aalborg Psychiatric Hospital, Centre for Psychosisresearch

Randomized, doubleblind, 4-arms, monocentric, interventinal Study for enhancing the efficacy of tDCS across from single intervention or Placebo by nicotinergic stimulation in schizophrenia.

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany

Sponsor

Klinikum der Universität München - AöR verteten durch den Vorstand des Bereiches Humanmedizin

Relapse prevention among schizophrenia: A multi stage controlled group study.

This study ended early.

Countries

United Kingdom

Sponsor

Department of Health

Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany, Sweden

Sponsor

Pfizer AB

The use of Oxytocin as adjunctive therapy for the treatment of schizophrenia: a randomized, double blind trial

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Italy

Sponsor

IRCCS CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI

Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects with Schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, Germany, Italy, + 1 other

Sponsor

Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium

Triiodothyronine as an adjunct in treatment of acute schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Lithuania

Sponsor

Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine

A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT...

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

France, United Kingdom, Belgium, + 6 others

Sponsor

SUNOVION PHARMACEUTICALS INC.

A 2-Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

Belgium, Bulgaria, Estonia, + 2 others

Sponsor

Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium